PhRMA Wants Amended ANDAs To Trigger 30-Month Stays
Executive Summary
FDA should specify that ANDAs which change certification from Paragraph III to Paragraph IV should trigger for a 30-month stay, the Pharmaceutical Research & Manufacturers of America states in comments on FDA's proposed rule
You may also be interested in...
FDA Generics Rule: Agency Will Scrutinize Paragraph III Switches, Troy Says
Generic firms that switch Paragraph III patent certifications to Paragraph IVs once the threat of a 30-month stay of approval is gone will be subject to increased scrutiny by FDA, Chief Counsel Daniel Troy said
FDA Generics Rule: Agency Will Scrutinize Paragraph III Switches, Troy Says
Generic firms that switch Paragraph III patent certifications to Paragraph IVs once the threat of a 30-month stay of approval is gone will be subject to increased scrutiny by FDA, Chief Counsel Daniel Troy said
GPhA Objection To Generic Drug Rule Could Backfire, FDA Counsel Troy Warns
The generic industry should consider carefully any attempt to derail FDA's regulatory approach to Waxman/Hatch reform, agency Chief Counsel Daniel Troy told the Generic Pharmaceutical Association